Calcium Oxalate Nephrolithiasis
Calcium oxalate nephrolithiasis, commonly known as kidney stone disease, is a prevalent medical condition characterized by the formation of solid masses within the kidneys. It is a common disorder[1], with a lifetime prevalence estimated at 4–9% in Japan and 8% in the United States [2]. The condition often recurs, with rates as high as 14% after one year and 35% after five years in the U.S., and nearly 60% of patients experiencing recurrence within ten years in Japan [2].
The biological basis of kidney stone formation primarily involves the crystallization of salts in the urine. Most kidney stones, approximately 80%, are composed of calcium oxalate or calcium phosphate crystals[2]. Stone formation occurs when urine becomes supersaturated with these salts and when concentrations of natural inhibitors, such as citrate, magnesium, pyrophosphate, uromodulin, and osteopontin, are low[2]. Factors contributing to urinary supersaturation include hypercalciuria (excessive calcium in urine), urinary tract infections, and alkaline urine [1]. Both environmental factors, such as diet, and genetic traits play a role in the mechanism of stone formation[2]. A strong genetic component is evident, as individuals with a family history of kidney stones are at a significantly higher risk, with studies estimating that up to 65% of stone formers have a familial predisposition [2]. Twin and genealogy studies further support the strong heritability of kidney stone disease[3], and genetic factors are known to influence urinary calcium excretion [4].
Clinically, calcium oxalate nephrolithiasis can cause severe acute back pain and, in some cases, lead to serious complications such as pyelonephritis or acute renal failure[1]. The high prevalence and recurrence rates place a significant burden on healthcare systems [2], impacting the cost and overall prevalence of urolithiasis [3]. The condition is also associated with an increased risk of chronic kidney disease[3]. Given its widespread occurrence, the potential for severe pain and complications, and the substantial healthcare costs, calcium oxalate nephrolithiasis represents a significant public health concern.
Limitations
Section titled “Limitations”Understanding the genetic underpinnings of calcium oxalate nephrolithiasis is a complex endeavor, and current research faces several limitations that warrant careful consideration when interpreting findings. These limitations span methodological challenges, generalizability issues, and the intricate interplay of genetic and environmental factors.
Methodological and Statistical Considerations
Section titled “Methodological and Statistical Considerations”Studies on calcium oxalate nephrolithiasis face several methodological and statistical limitations that can impact the interpretation of genetic findings. Some analyses, particularly those investigating genetic determinants of specific urinary traits, have been constrained by relatively modest sample sizes, potentially limiting the power to detect significant genetic associations for key risk factors like calcium excretion.[4] Furthermore, the composition of control cohorts in certain genome-wide association studies, which include individuals with a diverse range of unrelated medical conditions, could introduce cohort bias and complicate the attribution of genetic effects specifically to nephrolithiasis. [1]
Phenotypic characterization also presents challenges, as quantitative data for all relevant urinary risk factors are not consistently available across cohorts, and crucial dietary history, a known environmental contributor to stone formation, is often missing. [4]The potential influence of medications that affect urinary excretions (e.g., thiazides, allopurinol) or variable bone turnover on biomarker levels represents an unmeasured confounder.[4] Moreover, the reliance on estimated measures like estimated glomerular filtration rate (eGFR), derived from formulas, rather than direct physiological measurements, introduces variability and potential inaccuracies in phenotypic assessment. [1]
Generalizability and Phenotypic Heterogeneity
Section titled “Generalizability and Phenotypic Heterogeneity”A significant limitation is the generalizability of findings across diverse populations. Many large-scale genetic association studies have focused predominantly on specific ancestral groups, such as the Japanese population, meaning that identified genetic loci may not fully translate to populations with different genetic backgrounds. [1] Although trans-ethnic meta-analyses are emerging, these studies have sometimes revealed significant heterogeneity in genetic effects between populations, underscoring the need for more diverse cohorts to capture the full spectrum of genetic risk factors globally. [3] This lack of broad ancestral representation limits the applicability of current genetic insights to a worldwide patient population.
Environmental and Gene-Environment Interactions
Section titled “Environmental and Gene-Environment Interactions”The complex interplay between genetic predisposition and environmental factors, such as diet and lifestyle, poses a substantial challenge in fully elucidating the etiology of calcium oxalate nephrolithiasis. While environmental factors like low fluid intake, low dietary calcium, and high dietary salt are known to influence disease risk,[1] the absence of comprehensive quantitative dietary history in many cohorts precludes a thorough assessment of gene-environment interactions. [4] The observed lack of success in some dietary intervention studies to reduce recurrence suggests that the underlying mechanisms are more intricate than currently understood, highlighting a remaining knowledge gap in how these factors collectively contribute to stone formation. [1]
Despite strong evidence for the heritability of kidney stone disease and its associated biochemical traits, a significant portion of the genetic variance remains unexplained. Studies have noted that while many traits linked to stone risk possess a strong heritable component, genetic determinants for specific urinary traits are still largely unidentified.[4] For instance, despite being a key risk factor, comprehensive genetic associations for urinary calcium excretion have been elusive in some meta-analyses. [4] This “missing heritability” suggests that current genome-wide association study (GWAS) approaches may not fully capture the contributions of rare variants, complex epistatic interactions, or other genetic architectures, leaving substantial room for future discovery.
Variants
Section titled “Variants”MIR4455, a microRNA, and LINC02437, a long intergenic non-coding RNA, are integral components of the vast non-coding transcriptome, playing crucial regulatory roles in gene expression that are vital for maintaining cellular and physiological balance, including kidney function. These non-coding RNAs can influence various biological processes, from cell proliferation and differentiation to stress responses, which are all pertinent to renal health. The complex etiology of kidney stone formation, particularly calcium oxalate nephrolithiasis, is known to be influenced by a multitude of genetic factors that affect the kidney’s handling of ions and solutes[2]. Understanding the regulatory networks involving such non-coding RNAs can shed light on the genetic susceptibility to this common disorder, which is often characterized by imbalances in calcium-phosphate metabolism[1].
The single nucleotide polymorphism (SNP)rs56193428 , if located within or near the MIR4455 or LINC02437 genes, could significantly impact their expression, stability, or processing. SNPs in non-coding regions are increasingly recognized for their ability to alter gene regulation by modifying transcription factor binding sites, microRNA binding sites, or RNA secondary structures. Such genetic variations can lead to subtle yet profound changes in renal physiology, potentially affecting the kidney’s capacity to maintain proper fluid and electrolyte balance. For instance, disruptions in the tightly regulated paracellular transport of ions at epithelial tight junctions are critical factors in kidney stone development [2]. Therefore, rs56193428 might modulate an individual’s risk of nephrolithiasis by influencing these fundamental cellular processes, impacting parameters like serum phosphorus or estimated glomerular filtration rate (eGFR)[1].
The potential implications of rs56193428 , MIR4455, and LINC02437 for calcium oxalate nephrolithiasis lie in their capacity to dysregulate pathways involved in mineral homeostasis and kidney function. Altered activity of these non-coding RNAs, possibly mediated byrs56193428 , could affect the expression of genes that regulate calcium transport, oxalate metabolism, or the production of urinary crystallization inhibitors. This dysregulation could lead to an environment conducive to calcium oxalate crystal formation and aggregation in the renal tubules. Genetic studies consistently highlight the importance of maintaining proper ion homeostasis and calcium-phosphate metabolism to prevent the recurrence of kidney stones[2]. Thus, these variants and non-coding RNAs represent potential contributors to the genetic predisposition for recurrent kidney stone disease by influencing the delicate balance required for renal health[1].
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs56193428 | MIR4455 - LINC02437 | calcium oxalate nephrolithiasis |
Classification, Definition, and Terminology
Section titled “Classification, Definition, and Terminology”Definition and Core Terminology of Calcium Oxalate Nephrolithiasis
Section titled “Definition and Core Terminology of Calcium Oxalate Nephrolithiasis”Nephrolithiasis, commonly known as kidney stone disease, is a prevalent medical condition characterized by the formation of solid masses within the urinary tract.[1]These stones can cause severe acute back pain and may lead to serious complications such as pyelonephritis or acute renal failure.[1]Calcium oxalate nephrolithiasis specifically refers to the subtype where kidney stones are primarily composed of calcium oxalate crystals, which, along with calcium phosphate, constitute the majority (approximately 80%) of all kidney stones.[2]
The terms “nephrolithiasis” and “kidney stone” are used interchangeably to describe this disorder. [1] In clinical and research settings, the diagnosis of nephrolithiasis can be confirmed by enrolling physicians or identified through medical records using standardized codes such as ICD-10 and OPCS codes, or self-reported history of kidney stone surgery. [3] For genetic association studies, operational definitions often involve specific exclusions, such as patients with bladder stones, or secondary nephrolithiasis caused by drugs, hyperparathyroidism, or congenital anomalies of the urinary tract. [3], [1]
Classification of Nephrolithiasis and Contributing Factors
Section titled “Classification of Nephrolithiasis and Contributing Factors”Kidney stones are primarily classified by their chemical composition, with calcium oxalate and calcium phosphate being the most common types.[5], [2]Other recognized stone compositions include struvite, cystine, ammonium acid urate, and uric acid stones, which are often excluded in studies focusing on more common forms.[1] Beyond composition, nephrolithiasis can be broadly categorized into primary (idiopathic) and secondary forms, where secondary cases are those arising from identifiable causes like specific medications, hyperparathyroidism, or anatomical abnormalities of the urinary tract. [1]A specific subtype, hyperuricosuric calcium oxalate nephrolithiasis, is also recognized based on metabolic characteristics.[6]
The conceptual framework for stone formation centers on urinary supersaturation, a state where urine is oversaturated with stone-forming salts like calcium oxalate or calcium phosphate.[1], [2]This supersaturation is often induced by factors such as hypercalciuria, urinary tract infections, or alkaline urine, and is exacerbated when concentrations of natural stone inhibitors like citrate, magnesium, pyrophosphate, uromodulin, and osteopontin are low.[1], [2]Both environmental factors, including diet (e.g., low fluid intake, low dietary calcium, high dietary salt, Westernized diet, obesity, dehydration), and genetic predispositions contribute to the risk of stone formation.[2], [1]
Diagnostic and Risk Assessment Criteria
Section titled “Diagnostic and Risk Assessment Criteria”The clinical presentation of severe acute back pain is a key indicator of nephrolithiasis.[1]For a comprehensive understanding of stone risk and to guide management, various biochemical parameters are assessed. These include 24-hour urinary excretion of calcium, magnesium, uric acid, and urine volume, which are critical determinants of urinary supersaturation.[4]Additionally, serum levels of phosphorus, calcium, and urate, along with estimated glomerular filtration rate (eGFR) and body mass index (BMI), are evaluated as they represent systemic factors and metabolic traits associated with kidney stone risk.[1]
eGFR, for instance, is a calculated measure derived from blood test results, age, and gender, providing an assessment of kidney function. [1]The calculation of urinary saturation for calcium oxalate and calcium phosphate is a crucial measurement, often performed using specific computer programs, to gauge the propensity for crystal formation.[7]Magnesium is a known inhibitor of calcium oxalate and calcium phosphate crystallization, with urinary magnesium concentration affecting calculated supersaturation.[8], [7]While direct measurement of stone composition defines the calcium oxalate subtype, ongoing research also explores genetic determinants of urinary traits like calcium and magnesium excretion, acknowledging their strong heritable component and role as biomarkers in identifying individuals at higher risk for stone formation.[4]
Calcium oxalate nephrolithiasis, commonly known as kidney stone disease, is a prevalent condition characterized by the formation of calcium oxalate crystals within the urinary tract. The disease can lead to significant morbidity due to acute symptoms and a high propensity for recurrence, often necessitating medical intervention[1] [2].
Clinical Presentation and Symptomology
Section titled “Clinical Presentation and Symptomology”The most typical and prominent symptom of calcium oxalate nephrolithiasis is severe acute back pain, frequently referred to as renal colic[1]. This pain can range significantly in intensity, from discomfort to excruciating, and its presentation pattern is often acute and debilitating. Beyond pain, the condition can lead to severe complications such as pyelonephritis, a serious kidney infection, or acute renal failure, highlighting the potential for a broad spectrum of clinical phenotypes and severity ranges[1]. The disease is also characterized by a high recurrence rate, with studies indicating that nearly 60% of patients experience a recurrence within 10 years of their initial stone episode, and rates of 14% after one year and 35% after five years are observed in some populations, underscoring its chronic nature[1] [2].
Diagnostic Evaluation and Biochemical Indicators
Section titled “Diagnostic Evaluation and Biochemical Indicators”Diagnostic approaches for calcium oxalate nephrolithiasis primarily involve evaluating urinary composition and metabolic factors. Measurement methods include assessing urinary supersaturation with calcium oxalate or calcium phosphate, a critical factor in stone formation, often calculated using specific computer programs like EQUIL2[2] [4]. Hypercalciuria, an elevated excretion of calcium in the urine, is a significant objective measure and a primary metabolic abnormality contributing to stone development [1] [4]. Additionally, diagnostic tools involve 24-hour urine collections to quantify urinary levels of natural stone inhibitors such as citrate, magnesium, pyrophosphate, uromodulin, and osteopontin, as low concentrations of these substances correlate with increased stone risk[2] [4]. Genetic studies, including genome-wide association studies (GWAS), have identified specific genetic loci (e.g., 5q35.3, 7p14.3, and 13q14.1 in the Japanese population) and genes like CLDN14 and CASR associated with kidney stone risk and urinary calcium excretion, providing potential biomarkers and insights into individual susceptibility [1] [9] [10] [11] [12].
Variability, Risk Factors, and Recurrence
Section titled “Variability, Risk Factors, and Recurrence”The clinical presentation and risk of calcium oxalate nephrolithiasis demonstrate significant inter-individual variation and heterogeneity, influenced by both genetic and environmental factors. A strong genetic predisposition is a key prognostic indicator, with up to 65% of stone formers having a family history of the condition, and twin and genealogy studies confirming its heritability[2]. Phenotypic diversity is also observed across demographics; for instance, prevalence rates in individuals over 70 years old in Iceland show 10.1% for men versus 4.2% for women, and sex significantly influences urinary traits like urine volume and osmolality [2] [4]. Environmental factors, including diet, obesity, and dehydration, are established risk factors that contribute to the urinary milieu conducive to stone formation[1] [2]. The high recurrence rates, despite initial treatment, underscore the importance of identifying these diverse risk factors to implement targeted preventative strategies and improve long-term patient outcomes [1] [2].
Calcium oxalate nephrolithiasis, commonly known as kidney stone disease, arises from a complex interplay of genetic predispositions and environmental factors that disturb the delicate balance of urinary solutes. The formation of these stones, primarily composed of calcium oxalate or calcium phosphate, involves the supersaturation of urine with these salts and a deficiency in natural crystallization inhibitors[2]. Understanding the multifaceted causes is crucial for prevention and treatment.
Genetic Predisposition and Heritable Traits
Section titled “Genetic Predisposition and Heritable Traits”Genetic factors play a significant role in an individual’s susceptibility to calcium oxalate nephrolithiasis, with a strong heritable component evident in family, twin, and genealogy studies[13]; [14]; [3]; [15]; [16]; [17]; [18]; [19]; [20]. Up to 65% of kidney stone formers report a family history of the condition, underscoring this inherited risk [2]. Genome-wide association studies (GWAS) have identified several susceptible loci, including regions at 5q35.3, 7p14.3, and 13q14.1 in populations like the Japanese [1], and sequence variants in genes like CLDN14, which associates with kidney stones and bone mineral density[9].
Specific genetic variants influence calcium and magnesium homeostasis, impacting urinary excretion and stone formation. For instance, common and rare variants near the calcium-sensing receptor (CASR) gene are associated with serum calcium concentrations, and CASR gene polymorphisms can affect urinary calcium excretion in stone-forming patients [10]; [11]; [12]. Additionally, coding sequence variants in genes with kidney-specific expression, such as a Na/Pi co-transporter (NP003043.3:p.Tyr489Cys) and a Ca channel (NP_062815.2:p.Leu530Arg), have been linked to kidney stones and recurrent kidney stones [2]. Mutations in the _TRPM6gene, involved in magnesium transport, can lead to hypomagnesemia and subsequent hypocalcemia, indirectly contributing to stone risk[4]. The heritability of key urinary traits like calcium and magnesium excretion, and even urine volume, further highlights the polygenic nature of this condition[4]; [21].
Environmental and Lifestyle Factors
Section titled “Environmental and Lifestyle Factors”The formation of calcium oxalate stones is highly dependent on the urinary environment, particularly the degree of supersaturation with stone-forming salts. This supersaturation occurs when the concentrations of calcium oxalate or calcium phosphate in urine are high, or when the levels of natural inhibitors of stone formation, such as citrate, magnesium, pyrophosphate, uromodulin, and osteopontin, are low[2]. Greater excretion of urine calcium and altered excretion of uric acid are known risk factors, while magnesium acts as a calcium oxalate crystallization inhibitor, with higher urinary magnesium excretion potentially reducing stone risk[4].
Lifestyle and dietary choices significantly influence these urinary parameters. A “Westernized diet,” obesity, and dehydration are strongly associated with nephrolithiasis[1]. Specifically, obesity and weight gain have been identified as risk factors for kidney stones[22]. Maintaining a higher total urinary volume is a protective factor, as it dilutes stone-forming solutes and reduces supersaturation [4]. Societal changes, including dietary shifts, also contribute to evolving patterns of urolithiasis [23].
Complex Interactions and Other Modulators
Section titled “Complex Interactions and Other Modulators”Calcium oxalate nephrolithiasis often results from intricate gene-environment interactions, where an individual’s genetic predisposition is triggered or exacerbated by specific environmental and lifestyle factors. Twin studies have highlighted the combined influence of genetics and diet on nephrolithiasis risk[13]; [2]. For instance, while genetic factors influence urinary calcium excretion, these factors may differ between stone formers and controls, suggesting that the genetic impact is modulated by the disease state and other environmental exposures[4].
Beyond genetics and environment, several other factors contribute to stone formation. Comorbidities such as hypercalciuria, urinary tract infections, and alkaline urine directly promote urinary supersaturation and stone formation [1]. Obesity, as a comorbidity, also significantly increases risk[22]; [1]. Furthermore, certain medications, including thiazides and allopurinol, can influence urinary excretions of relevant solutes, thereby modifying an individual’s risk for stone formation [4]. The prevalence of kidney stones also tends to increase with age, with rates higher in older populations [2].
Biological Background
Section titled “Biological Background”Calcium oxalate nephrolithiasis, commonly known as kidney stone disease, is a prevalent disorder characterized by the formation of solid masses within the urinary tract. These stones, predominantly composed of calcium oxalate or calcium phosphate crystals, can lead to severe acute back pain and serious complications such as pyelonephritis or acute renal failure ,[10]. Activation of CASR in tissues like the parathyroid glands and kidneys initiates intracellular signaling cascades that modulate parathyroid hormone (PTH) secretion and renal calcium reabsorption, thereby forming a critical feedback loop to stabilize circulating calcium levels[24].
In the context of nephrolithiasis, even subtle perturbations in CASR signaling or its downstream effectors can contribute to hypercalciuria, characterized by excessive calcium excretion in the urine [2]. This elevated urinary calcium concentration, combined with oxalate, drives the supersaturation of urine, which is a primary prerequisite for calcium oxalate crystal nucleation and growth[2]. Therefore, dysregulation within these renal regulatory pathways, including those affecting the 24-hour urinary excretion of calcium, directly impacts an individual’s susceptibility to stone formation [4].
Genetic and Proteomic Determinants of Stone Risk
Section titled “Genetic and Proteomic Determinants of Stone Risk”Genetic predisposition significantly influences the risk of calcium oxalate nephrolithiasis, as evidenced by strong heritability and the identification of common and rare genetic variants linked to kidney stones and associated biochemical traits[2]. These genetic variations can alter gene regulation, impacting the expression levels of proteins involved in crucial processes such as renal ion transport, crystal formation, or the activity of crystallization inhibitors. Furthermore, post-translational modifications, like phosphorylation or glycosylation, can modulate protein activity and stability, thereby affecting their functional roles within the complex renal environment.
Systems-level integration highlights how genetic variations converge with the proteome to influence disease risk. Research connecting genetic risk to disease endpoints has utilized the human blood plasma proteome, demonstrating how specific protein quantitative trait loci (pQTLs) can affect circulating protein levels[25], [26]. This proteo-genomic convergence offers insights into how genetic variants translate into altered protein function or abundance, potentially explaining individual susceptibility to calcium oxalate nephrolithiasis by affecting proteins that modulate urinary composition or crystal-cell interactions[27].
Metabolic Flux and Inhibitor Balance
Section titled “Metabolic Flux and Inhibitor Balance”The formation of calcium oxalate stones is critically dependent on the balance of metabolic pathways governing the urinary concentrations of both stone-forming ions and natural inhibitors. Oxalate, a primary constituent of these stones, is an end-product of metabolism, and its biosynthesis and catabolism are tightly regulated to maintain physiological levels[2]. Dysregulation in metabolic flux, such as increased endogenous oxalate production or impaired degradation, directly contributes to hyperoxaluria, significantly increasing the risk of stone formation[2].
Beyond oxalate, the urinary concentrations of natural stone inhibitors such as citrate, magnesium, and pyrophosphate are crucial protective factors[2]. Low levels of these inhibitors, whether due to metabolic dysregulation, altered renal handling, or dietary influences, diminish the urine’s capacity to prevent crystal nucleation, growth, and aggregation. Metabolic GWAS studies have begun to identify genetic influences on various metabolites, including those relevant to stone formation, suggesting that inherited differences in metabolic regulation and flux control play a significant role in determining an individual’s susceptibility to calcium oxalate nephrolithiasis[28], [29].
Integrated Molecular Networks in Lithogenesis
Section titled “Integrated Molecular Networks in Lithogenesis”Calcium oxalate nephrolithiasis arises from the intricate interplay of multiple molecular pathways, extending beyond simple supersaturation to involve complex network interactions and crosstalk among various cellular and systemic processes. For instance, signaling pathways that regulate renal calcium handling can influence metabolic pathways affecting oxalate or citrate excretion, demonstrating a hierarchical regulation where changes in one system propagate to others[2]. These network interactions are not isolated but form an integrated system, where genetic predispositions combine with environmental factors to create emergent properties that define an individual’s lithogenic risk.
The dysregulation within these integrated molecular networks ultimately leads to the pathological conditions favoring stone formation. While compensatory mechanisms may initially counteract imbalances, their eventual failure contributes to chronic stone disease. Identifying critical nodes within these networks, where multiple pathways converge or diverge, offers promising avenues for therapeutic intervention[2]. For example, targeting specific transporters, enzymes, or receptors that are central to maintaining urinary homeostasis or preventing crystal aggregation could mitigate the progression of calcium oxalate nephrolithiasis.
Population Studies
Section titled “Population Studies”Population studies on calcium oxalate nephrolithiasis have illuminated its global burden, demographic patterns, and complex genetic and environmental underpinnings. Large-scale epidemiological research, including cohort studies and biobank analyses, provides critical insights into prevalence, recurrence, and risk factors across diverse populations, while also highlighting the methodological approaches necessary for comprehensive understanding.
Epidemiological Landscape and Population Demographics
Section titled “Epidemiological Landscape and Population Demographics”Calcium oxalate nephrolithiasis is a common disorder with significant prevalence and recurrence rates across different populations. In the United States, the lifetime prevalence is estimated at 8%, with a high recurrence rate of 14% after one year and 35% after five years[2]. Japan reports a lifetime prevalence ranging from 4% to 9%, where approximately 60% of patients experience recurrence within 10 years following initial treatment [1]. Epidemiological findings indicate that demographic factors, such as a Westernized diet, obesity, and dehydration, are associated with an increased risk of nephrolithiasis[1].
Geographic variations in prevalence and incidence are also observed. For instance, in Iceland, the prevalence among individuals older than 70 years is notably higher in men (10.1%) compared to women (4.2%) [2]. These population-specific patterns suggest that environmental factors, alongside genetic predispositions, contribute to the observed differences in disease burden. Studies also indicate that societal changes can impact the patterns of urolithiasis, underscoring the dynamic nature of these epidemiological trends[1].
Genetic Determinants and Heritability
Section titled “Genetic Determinants and Heritability”Genetic factors play a substantial role in the susceptibility to calcium oxalate nephrolithiasis, with a strong heritable component identified across various populations. Research indicates that up to 65% of individuals who form kidney stones have a family history of the condition[2]. Twin studies, such as those from the Vietnam Era Twin Registry and more recent analyses, have consistently reported strong heritability for kidney stone disease, highlighting the genetic contribution to renal function and electrolyte balance[17]. Further evidence from genealogy studies and analyses in populations like Sweden also confirms significant familial risks for urolithiasis [15].
Large-scale genome-wide association studies (GWAS) have identified specific genetic loci associated with nephrolithiasis and related biochemical traits. In the Japanese population, a GWAS identified novel susceptible loci at 5q35.3, 7p14.3, and 13q14.1 [1]. Similarly, studies have implicated common and rare variants, including those in the CLDN14 gene, with kidney stone risk and bone mineral density[2]. Meta-analyses of GWAS for serum calcium concentrations have also pinpointed significantly associated single nucleotide polymorphisms (SNPs) near genes like the calcium-sensing receptor (CASR), which are crucial for calcium homeostasis[10]. Moreover, genetic determinants of urinary traits such as calcium, magnesium, and uric acid excretion, which are critical for kidney stone risk, have been explored through meta-analyses of large cohorts, revealing their own heritable components[4].
Methodological Approaches in Population-Level Research
Section titled “Methodological Approaches in Population-Level Research”Population-level research on calcium oxalate nephrolithiasis employs diverse and robust methodologies to uncover its complexities. Large-scale cohort studies are fundamental, exemplified by the UK Biobank, a prospective cohort study involving approximately 500,000 individuals aged 40 to 69 years. This resource integrates whole-genome genotyping data with medical records, enabling the identification of thousands of cases based on diagnostic codes and self-reported surgical history[3]. Similarly, BioBank Japan has provided DNA samples from thousands of nephrolithiasis patients, combined with controls from population-based cohorts like the JPHC (Japan Public Health Center)-based prospective study and J-MICC [3].
These studies often utilize genome-wide association studies (GWAS) and meta-analyses, combining data from multiple cohorts to increase statistical power and broaden generalizability. For instance, a meta-analysis of several large cohorts, including GENOA, the Nurses’ Health Study (NHS), NHS II, the Health Professionals Follow-up Study (HPFS), and PRE-VEND, investigated genetic determinants of 24-hour urinary excretion of calcium, magnesium, and uric acid[4]. While such studies provide invaluable insights, methodological considerations include the representativeness of the sample populations. For example, some analyses involve cohorts of mixed European ancestry, and researchers acknowledge that genetic features associated with calcium excretion might differ in these populations compared to more homogeneous groups like the Icelandic population [4]. Furthermore, distinguishing genetic factors relevant to urinary calcium excretion between stone formers and controls remains an area for continued investigation [4].
Frequently Asked Questions About Calcium Oxalate Nephrolithiasis
Section titled “Frequently Asked Questions About Calcium Oxalate Nephrolithiasis”These questions address the most important and specific aspects of calcium oxalate nephrolithiasis based on current genetic research.
1. My dad had kidney stones; will I get them too?
Section titled “1. My dad had kidney stones; will I get them too?”Yes, you are at a significantly higher risk if kidney stones run in your family. Studies show that up to 65% of people who form stones have a familial predisposition. This strong genetic component means you’ve likely inherited some of the tendencies that contribute to stone formation.
2. I had a stone; will I definitely get another one?
Section titled “2. I had a stone; will I definitely get another one?”There’s a high chance you will experience another stone. Recurrence rates are substantial, with studies showing rates as high as 14% after one year, 35% after five years, and nearly 60% within ten years. Both genetic factors and lifestyle choices contribute to this high recurrence.
3. My sibling gets stones, but I don’t; why the difference?
Section titled “3. My sibling gets stones, but I don’t; why the difference?”It’s a complex interplay of both your genetic makeup and individual lifestyle factors. While there’s a strong genetic predisposition to stone formation, subtle differences in diet, fluid intake, and other environmental factors can lead to different outcomes even among family members. Your genes influence traits like urinary calcium excretion, but your daily habits also play a crucial role.
4. Does my diet really matter if stones run in my family?
Section titled “4. Does my diet really matter if stones run in my family?”Absolutely, your diet matters greatly. Both genetic traits and environmental factors, such as diet, significantly influence stone formation. Eating a diet with low fluid intake, low dietary calcium, or high dietary salt can increase your risk, even with a genetic predisposition.
5. Can a DNA test tell me if I’ll get kidney stones?
Section titled “5. Can a DNA test tell me if I’ll get kidney stones?”A DNA test can provide insights into your genetic risk factors, but it can’t give a definitive “yes” or “no.” Genetic studies have identified variants linked to stone risk and related urinary traits, but a significant portion of the genetic influences (known as “missing heritability”) is still being researched. Lifestyle and diet also play a major role in whether stones actually form.
6. Will my kids inherit my tendency to get stones?
Section titled “6. Will my kids inherit my tendency to get stones?”Yes, there’s a strong likelihood your children could inherit a predisposition to kidney stones. The condition has a significant heritable component, with genetic factors influencing key risk traits like urinary calcium excretion. This means your children will likely have a higher baseline risk compared to the general population.
7. Does drinking lots of water truly prevent all stones?
Section titled “7. Does drinking lots of water truly prevent all stones?”While drinking plenty of water is incredibly important and a primary preventive measure, it won’t prevent all stones for everyone. Low fluid intake is a major risk factor, as it helps prevent urine from becoming supersaturated with stone-forming salts. However, genetics, other dietary factors, and the levels of natural inhibitors in your urine also play roles, meaning some people may still form stones despite good hydration.
8. Why do some people never get stones, no matter what?
Section titled “8. Why do some people never get stones, no matter what?”This is often due to a fortunate combination of their genetic makeup and individual physiology. Some individuals may have genetic profiles that lead to higher levels of natural stone inhibitors (like citrate) or lower urinary calcium excretion, making them less prone to stone formation. Their overall lifestyle and diet also contribute, even if they don’t seem overtly “strict” about it.
9. Does my family’s background affect my stone risk?
Section titled “9. Does my family’s background affect my stone risk?”Yes, your ancestral background can influence your specific stone risk. Many large-scale genetic studies have focused on particular populations, like the Japanese, and findings can show significant differences in genetic effects between various ethnic groups. This means your specific background might be associated with distinct genetic risk factors.
10. Can I overcome my family stone history with diet?
Section titled “10. Can I overcome my family stone history with diet?”You can significantly reduce your risk of developing stones, even with a strong family history, but it’s more about managing than entirely “overcoming.” While genetics provide a predisposition, environmental factors like diet are equally crucial. Adopting a healthy diet – including adequate fluid intake, balanced calcium, and lower salt – can effectively counteract many genetic tendencies and help prevent stone formation.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Urabe, Y. “A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible Loci at 5q35.3, 7p14.3, and 13q14.1.” PLoS Genet, vol. 8, no. 3, 2012, p. e1002541.
[2] Oddsson A et al. “Common and rare variants associated with kidney stones and biochemical traits.” Nat Commun, vol. 6, 2015, 7579. PMID: 26272126.
[3] Howles, S. A. et al. “Genetic variants of calcium and vitamin D metabolism in kidney stone disease.”Nat Commun, vol. 10, no. 1, 2019, 5174. PMID: 31729369.
[4] Ware EB et al. “Genome-wide Association Study of 24-Hour Urinary Excretion of Calcium, Magnesium, and Uric Acid.”Mayo Clin Proc Innov Qual Outcomes, vol. 3, no. 4, 2019, pp. 448-460. PMID: 31993563.
[5] Coe, F. L., et al. “Kidney stone disease.”J Clin Invest, vol. 115, no. 10, 2005, pp. 2598–2608.
[6] Coe, F. L. “Hyperuricosuric calcium oxalate nephrolithiasis.”Adv Exp Med Biol, vol. 128, 1980, pp. 439-450.
[7] Werness, P. J., et al. “EQUIL2: a BASIC computer program for the calculation of urinary saturation.” J Urol, vol. 134, no. 6, 1985, pp. 1242-1244.
[8] Li, M. K., et al. “Effects of magnesium on calcium oxalate crystallization.”J Urol, vol. 133, no. 1, 1985, pp. 123-125.
[9] Thorleifsson, G. et al. “Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density.”Nat Genet, vol. 41, no. 9, 2009, pp. 926-930.
[10] Kapur K et al. “Genome-wide meta-analysis for serum calcium identifies significantly associated SNPs near the calcium-sensing receptor (CASR) gene.” PLoS Genet, vol. 6, no. 7, 2010, e1001035. PMID: 20661308.
[11] O’Seaghdha CM et al. “Meta-analysis of genome-wide association studies identifies six new Loci for serum calcium concentrations.” PLoS Genet, vol. 9, no. 9, 2013, e1003796. PMID: 24068962.
[12] Vezzoli, G. et al. “Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients.” J Am Soc Nephrol, vol. 13, no. 10, 2002, pp. 2517-2523.
[13] Goldfarb, D. S., Fischer, M. E., Keich, Y., & Goldberg, J. “A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry.” Kidney Int, vol. 67, no. 3, 2005, pp. 1053-1061.
[14] Edvardsson, Vidar O., et al. “Familiality of kidney stone disease in Iceland.”Scandinavian Journal of Urology and Nephrology, vol. 43, no. 5, 2009, pp. 420-424.
[15] Hemminki, K. et al. “Familial risks in urolithiasis in the population of Sweden.” BJU Int., vol. 121, 2018, pp. 479–485.
[16] Hunter, D. J. et al. “Genetic contribution to renal function and electrolyte balance: a twin study.” Clin. Sci., vol. 103, 2002, pp. 259–265.
[17] Goldfarb, D. S. et al. “A twin study of genetic influences on nephrolithiasis in women and men.” Kidney Int. Rep., vol. 4, 2019, pp. 535–540.
[18] Curhan, G. C., Willett, W. C., Rimm, E. B., & Stampfer, M. J. “Family history and risk of kidney stones.” J Am Soc Nephrol, vol. 8, no. 10, 1997, pp. 1568-1573.
[19] McGeown, Michael G. “Heredity in renal stone disease.”Clinical Science, vol. 19, 1960, pp. 465-471.
[20] Stechman, Michael J., et al. “Genetics of hypercalciuric nephrolithiasis: renal stone disease.”Annals of the New York Academy of Sciences, vol. 1116, 2007, pp. 461-484.
[21] Lieske, John C., et al. “Heritability of urinary traits that contribute to nephrolithiasis.” Clinical Journal of the American Society of Nephrology, vol. 9, no. 5, 2014, pp. 943-950.
[22] Taylor, Eric N., et al. “Obesity, weight gain, and the risk of kidney stones.”JAMA, vol. 293, no. 4, 2005, pp. 455-462.
[23] Zilberman, D. E., Yong, D., & Albala, D. M. “The impact of societal changes on patterns of urolithiasis.” Curr Opin Urol, vol. 20, no. 2, 2010, pp. 148-153.
[24] Chang X et al. “Genome-wide association study of serum minerals levels in children of different ethnic background.” PLoS One, vol. 10, no. 4, 2015, e0122921. PMID: 25886283.
[25] Suhre K et al. “Connecting genetic risk to disease end points through the human blood plasma proteome.”Nat Commun, vol. 8, 2017, 14367. PMID: 28240269.
[26] Sun BB et al. “Genomic atlas of the human plasma proteome.” Nature, 2018. PMID: 29875488.
[27] Pietzner M et al. “Mapping the proteo-genomic convergence of human diseases.” Science, vol. 374, no. 6567, 2021, eabj1541. PMID: 34648354.
[28] Al-Khelaifi F et al. “Metabolic GWAS of elite athletes reveals novel genetically-influenced metabolites associated with athletic performance.” Sci Rep, vol. 9, no. 1, 2019, 19932. PMID: 31882771.
[29] Rhee EP et al. “A genome-wide association study of the human metabolome in a community-based cohort.” Cell Metab, vol. 18, no. 1, 2013, pp. 130-43. PMID: 23823483.